
Melisa Wong lays out the findings of a study she did looking at the age of patients with recurrent lung cancer and the likelihood they were to receive active treatment.

Melisa Wong lays out the findings of a study she did looking at the age of patients with recurrent lung cancer and the likelihood they were to receive active treatment.

Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology, Aging Research T32 Fellow, University of California San Francisco Geriatrics, discusses the impact that comorbidities have on the treatment for lung cancer.

Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology at the University of California San Francisco, discusses differences among age groups in the treatment of non–small cell lung cancer (NSCLC).

Melisa Wong, MD, discusses an analysis of age and comorbidity on treatment of non-small cell lung cancer recurrence. Wong presented this analysis at the 2016 ASCO Annual Meeting.

Published: June 4th 2016 | Updated:

Published: July 25th 2016 | Updated:

Published: August 9th 2016 | Updated:

Published: September 22nd 2016 | Updated: